FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPE	ROVAL
OMB Number:	3235-0287
Estimated average	burden
hours per response	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe response														
Name and Address of Reporting Person * Pepose Jay			2. Issuer Name and Ticker or Trading Symbol Ocuphire Pharma, Inc. [OCUP]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X_Director 10% Owner						
	JPHIRE P	(First) HARMA, INC., VE, SUITE 120		3. Date of Earliest Transaction (Month/Day/Year) 04/08/2022				Officer (give title below) Other (specify below)				w)			
(Street) FARMINGTON HILLS, MI 48335			4. If Amendment, Date Original Filed(Month/Day/Year)						_X_	6. Individual or Joint/Group Filing(Check Applicable Line) X_ Form filed by One Reporting Person Form filed by More than One Reporting Person					
(Cit	y)	(State)	(Zip)	Table I - Non-Derivative Securities Acqu			s Acquired	ired, Disposed of, or Beneficially Owned							
1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year		2A. Deemed Execution Da any (Month/Day/		Date, if Code (Inst		(/	Securities Acq A) or Disposed onstr. 3, 4 and 5)			ing Reported		6. Ownership Form: Direct (D) or Indirect (I)	Beneficial Ownership		
							Cod	e V A	mount (D)	Price				(Instr. 4)	
Reminder:	Report on a s	separate line for each	class of securities	beneficial	lly own	ea aire	ctiy c	Person	s who respon orm are not r					ned SEC	1474 (9-02)
Reminder:	Report on a s	separate line for eacl		Derivati	ive Sec	ırities	Acquants,	Person in this f display uired, Dispo options, co	s who respon form are not r s a currently esed of, or Bene nvertible secur	equired to valid OMB ficially Ow	respond control r	unless the number.	e form		1474 (9-02)
1. Title of	2. Conversion	3. Transaction	Table II - 3A. Deemed Execution Date, if	Derivati (e.g., put 4. Transaci Code	ive Sects, calls 5. tion of Se or of (II	irities , warr	Acquants, er ntive s l (A) sed	Person in this f display uired, Dispo options, co	s who responderm are not respondered of, or Bendervertible securicisable and	equired to valid OMB ficially Ow	o respond B control r wned d Amount ying	unless the number.	9. Number Derivative Securities Beneficially Owned Following Reported Transaction	of 10. Owners! Form of Derivati Security Direct (1) or Indire	11. Natur of Indire Benefici Ownersl (Instr. 4)
1. Title of Derivative Security	2. Conversion or Exercise Price of Derivative	3. Transaction Date	Table II - 3A. Deemed Execution Date, if any	Derivati (e.g., put 4. Transaci Code	tive Section of Section of Official (II an	Number Deriver Curities quired Dispos (D) str. 3, 15)	Acquants, er attive s l (A) sed 4,	Personin this findisplay uired, Disponions, co 6. Date Exe Expiration	s who responderm are not rest a currently resed of, or Benear recisable and Date recisabl	ricially Ownities) 7. Title and of Underly Securities	o respond B control r wned d Amount ying	8. Price of Derivative Security	9. Number Derivative Securities Beneficially Owned Following Reported	of 10. Owners! Form of Derivati Security Direct (l or Indire	11. Natur of Indire Benefici Ownersl (Instr. 4)

Reporting Owners

Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Pepose Jay C/O OCUPHIRE PHARMA, INC. 37000 GRAND RIVER AVE, SUITE 120 FARMINGTON HILLS, MI 48335	X			

Signatures

/s/ Emily J. Johns, by Power of Attorney	04/13/2022	
**Signature of Reporting Person	Date	

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The option will vest with respect to 12,500 shares on March 31, 2023, and then with respect to 1,041 shares on the last day of each month from April 2023 through February 2026 and with respect to 1,065 shares at the end of March 2026, subject to the Reporting Person's continuing service through each applicable vesting date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.